cd19 allo-car-t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 20, 2020 (NCT04516551)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04516551 | Phase 1 | Nov 20, 2020 | Anhui Medical University, Chongqing Medical University, Gracell Biotechnology Ltd., Guizhou Medical University, People's Liberation Army of China, Zhejiang University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Chongqing Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Gracell Biotechnology Ltd. | For profit | 1 | 0 | 1 | 2020 |
| Guizhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2020 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1